The Cooper Companies, Inc.

COO Healthcare Medical - Instruments & Supplies NASDAQ

PDF Back to Search

$81.40

+$4.37 (+5.67%)

Open: $87.50 | High: $89.83 | Low: $80.90 | Prev Close: $77.03

Market Cap: $16.24B

Volume: 9.2M | Avg: 2.7M

Last updated: December 05, 2025 at 10:01 PM
Investment Rating
B

Neutral

Overall Score: 60/100

Rating Breakdown:
DCF Score 3/5
60%
Neutral
ROE Score 3/5
60%
Neutral
ROA Score 4/5
80%
Buy
D/E Score 2/5
40%
Sell
P/E Score 1/5
20%
Strong Sell
P/B Score 3/5
60%
Neutral
Add to Watchlist Add to Portfolio
Stock Score Analysis
D

Stock Score: 535

Comprehensive Quality Assessment

Component Breakdown:
Efficiency 10
Financial Health 60
Growth 55
Market Sentiment 10
Risk 50
Lower is better
Valuation 15
Momentum 35
View Full Stock Score Dashboard
Valuation Metrics
Valuation Ratios
P/E Ratio 39.90
P/B Ratio 1.96
P/S Ratio 3.97
EPS $2.04
Beta 1.05
Shares Outstanding 199.50M
Price Range & Moving Averages
52-Week High $101.53
52-Week Low $61.78
SMA 50 $71.79
SMA 200 $74.92
Earnings
Next Earnings December 04, 2025 09:00 PM ET
Financial Ratios
Margins
Gross Margin 65.5%
Operating Margin 16.7%
Net Margin 9.2%
Returns
ROE 4.5%
ROA 3.0%
Liquidity & Leverage
Debt/Equity 0.30
Current Ratio 1.89
Quick Ratio 1.13
Balance Sheet
Total Assets $12.39B
Total Liabilities $4.16B
Total Equity $8.24B
Cash $110.60M
Total Debt $47.80M
Net Debt $-62,800,000
Income Statement
Revenue $4.09B
Gross Profit $2.68B
Operating Income $682.90M
Net Income $374.90M
EBITDA $666.50M
Revenue/Share $20.66
Cash Flow
Operating CF $796.10M
CapEx $362.40M
Free Cash Flow $433.70M
Book Value/Share $41.59
Tangible Book/Share $14.13
Equity/Share $41.59
Technical Indicators
RSI (14) 69.19 Neutral
MACD
1.66 Signal: 1.41
Volatility 26.55%
Trading Signal Bullish
Performance & Returns
Total Returns
1 Year -5.85%
Risk-Adjusted Returns
Sharpe Ratio -0.39 Poor
Volatility (Ann.) 38.33% Moderate
vs S&P 500 (SPY)
COO (1Y) -5.85%
S&P 500 (1Y) +11.86%
Alpha (Excess Return) -17.72%
Risk-free rate: 4.5% (3-month US Treasury) • Based on 199 trading days
Sector Comparison (Healthcare)
Compared to 59 peers in Healthcare
Metric COO Sector Avg Percentile
P/E Ratio 39.9 31.05 76%
P/B Ratio 1.96 -0.59 32%
ROE (%) 4.54% 9.89% 22%
Net Margin (%) 9.16% 10.06% 42%
Stock Score 535 503.0 63%
1Y Return (%) -5.85% +4.60% 32%
Percentile: 0% = worst in sector, 100% = best in sector
Historical Price Analysis (Last 200 Days)
Technical Analysis
Ticker Close SMA 5 SMA 8 SMA 13 SMA 50 SMA 200 RSI (14) MACD Volatility (%) Volume Signal SMA Decision
COO $81.40 $76.84 $77.04 $75.28 $71.79 $74.92 69.19 1.66 26.55% 5125367 Neutral Mixed
Candlestick Patterns

There wasn't any recognizable pattern for the COO stock

News Sentiment
📊 Ticker 📰 Headline 💭 Sentiment 📡 Source 🔗 URL
COO Victoria's Secret, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Friday Positive feeds.benzinga.com Read More
COO The Cooper Companies, Inc. (COO) Q4 2025 Earnings Call Transcript Neutral seekingalpha.com Read More
COO The Cooper Companies (COO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates Neutral zacks.com Read More
COO The Cooper Companies (COO) Q4 Earnings and Revenues Surpass Estimates Neutral zacks.com Read More
COO Cooper Companies initiates strategic review; shares jump Neutral reuters.com Read More
Company Information

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

CEO Albert G. White
Employees 16000
Country US
IPO Date 1983-01-21
Exchange NASDAQ
Website https://www.coopercos.com
Sector Healthcare
Industry Medical - Instruments & Supplies
Similar Stocks (Healthcare - Medical - Instruments & Supplies)
ISRG

Intuitive Surgical, Inc.

Price: $575.34
Change: +1.18%
Market Cap: $2055B
P/E: 75.90
Score: D (590)
View Details
BDX

Becton, Dickinson and Company

Price: $193.96
Change: +0.10%
Market Cap: $5559B
P/E: 33.27
Score: E (460)
View Details
RMD

ResMed Inc.

Price: $256.55
Change: +2.00%
Market Cap: $3759B
P/E: 26.23
Score: C (620)
View Details
WST

West Pharmaceutical Services, Inc.

Price: $280.23
Change: -0.55%
Market Cap: $2016B
P/E: 41.58
Score: D (545)
View Details
Rating Metrics Explained
DCF Score (Discounted Cash Flow)

Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.

ROE Score (Return on Equity)

Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.

ROA Score (Return on Assets)

Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.

D/E Score (Debt-to-Equity)

Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.

P/E Score (Price-to-Earnings)

Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.

P/B Score (Price-to-Book)

Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.

Rating Recommendations:

Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:

  • Strong Buy (5/5): Excellent score - strong positive indicator
    • The metric significantly outperforms industry averages (top 20% of companies)
    • Indicates exceptional financial health or attractive valuation in that category
  • Buy (4/5): Good score - positive indicator
    • Above-average performance (top 40% of companies)
    • Shows strong fundamentals with room for improvement
  • Neutral (3/5): Average score - neutral indicator
    • Performance in line with industry median (middle 20%)
    • Neither significantly positive nor negative signal
  • Sell (2/5): Below average - negative indicator
    • Below-average performance (bottom 40% of companies)
    • Suggests weakness in this particular metric
  • Strong Sell (1/5): Poor score - strong negative indicator
    • Significantly underperforms industry (bottom 20%)
    • Indicates potential risk or overvaluation in that category
Note: The overall rating combines all six component scores to provide a comprehensive investment assessment. No single metric should be used in isolation for investment decisions.